Home/Filings/4/0001144204-17-021380
4//SEC Filing

PLx Pharma Inc. 4

Accession 0001144204-17-021380

CIK 0001497504operating

Filed

Apr 19, 8:00 PM ET

Accepted

Apr 20, 9:15 PM ET

Size

7.7 KB

Accession

0001144204-17-021380

Insider Transaction Report

Form 4
Period: 2017-04-19
Giordano Natasha
DirectorCEO
Transactions
  • Award

    Common Stock

    2017-04-19+1,0861,086 total
  • Award

    Options

    2017-04-19+216,580216,580 total
    Exercise: $12.44Exp: 2025-09-25Common Stock (216,580 underlying)
Footnotes (3)
  • [F1]Received in exchange for 1,380 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
  • [F2]Received in connection with the Merger in exchange for an employee stock option to buy 275,000 shares of PLx Opco Inc. common stock for $9.80 per share.
  • [F3]The option is exercisable as to 108,290 shares as of the date hereof, and will become exercisable as to an additional 54,145 shares on each of January 1, 2018 and (subject to continued employment through such date) January 1, 2019.

Issuer

PLx Pharma Inc.

CIK 0001497504

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001497504

Filing Metadata

Form type
4
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 9:15 PM ET
Size
7.7 KB